

PP18

R Shiny Application to Optimize Review of Multiple Myeloma Efficacy Data Listings


Dinesh Putluri (*dinesh.putluri@bms.com*)

Introduction

In Multiple Myeloma studies, SAS-generated listings containing biochemical test results, BMA, BMB, bone lesion, and plasmacytomas data are pivotal for adjudication. These listings, typically presented in RTF/PDF formats, underpin crucial efficacy evaluations. However, the manual review process involving data quality checks and efficacy assessments becomes increasingly cumbersome, particularly in larger studies.

Key challenges

- Labor-Intensive Process:** Manual annotation and review of large datasets.
- Timeliness:** Delays in assessing data quality and efficacy due to manual methods.
- Complexity:** Handling diverse data types for comprehensive assessments.






Benefits

- Efficiency Boost:** Accelerated data review process for timely and insightful conclusions.
- Data Integrity:** Thorough data quality checks ensuring reliability.
- Enhanced Collaboration:** Improved communication among clinical teams.

Innovative Solution

As a transformative solution, BMS has pioneered an intuitive web application using R Shiny. This innovative approach empowers clinical teams by:

- Personalized Data Scrutiny:** Enabling tailored filtering based on panels, subjects and visits.
- Comparative Analysis:** Supporting side-by-side or stacked report comparisons.
- Seamless Collaboration:** Integrated note-taking facilitating team collaboration and discussion.



Conclusion

- BMS's innovative approach significantly enhances the clinical efficacy data review process, promising streamlined, efficient, and comprehensive evaluations for Multiple Myeloma studies.
- The integration of R Shiny's web application transforms the landscape of data assessment, driving towards more efficient and insightful conclusions.